Skinny, Inc. Part 2: The big business of Ozempic
You can listen to the first episode of this three-part series here.
GLP-1 medications to treat diabetes, obesity and several other illnesses have exploded in popularity since Ozempic was approved for use in Canada back in 2018. Ozempic and Wegovy, the GLP-1s which contain semaglutide, are the third-most prescribed drug in Canada, and by far the best-selling one.
Chris Hannay, The Globe’s business of health reporter, will explain why the introduction of generic semaglutide will mean lower prices and more options for Canadians. And we’ll explore access to these drugs with The Globe’s health…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.